UCH-L1 can be classified within the AT(N) framework as an N-Neuronal injury biomarker: [1]
| AT(N) Category | Classification | Rationale | [2]
|---------------|----------------|-----------| [3]
| A (Amyloid) | Not applicable | UCH-L1 is not an amyloid marker | [4]
| T (Tau) | Not applicable | UCH-L1 is not a tau marker | [5]
| N (Neurodegeneration) | N-Neuronal injury | Released from damaged neurons; indicates acute and chronic neuronal injury | [6]
UCH-L1 provides complementary information to NfL and NfH, with distinct kinetics - it peaks earlier (24-48 hours) following acute injury versus NfL/NfH which peak at 1-2 weeks. [7]
Uch L1 Neuronal Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [8]
Category: Biomarker [@uchla] [9]
Target: UCH-L1 protein [@uchlb] [10]
Sample Type: CSF, Blood (plasma/serum) [@uchlc] [11]
Diseases: Alzheimer's Disease, Parkinson's Disease, Traumatic Brain Injury, ALS, Huntington's Disease [@uchld] [12]
Sensitivity: High (ng/mL range in CSF) [@uchle]
Specificity: Moderate (elevated in multiple conditions) [@banyan]
Ubiquitin C-terminal Hydrolase L1 (UCH-L1), also known as PGP9.5 (Protein Gene Product 9.5), is a neuron-specific enzyme that constitutes 1-5% of total brain protein. It functions as a deubiquitinating enzyme in the ubiquitin-proteasome system (UPS) and is highly enriched in neurons throughout the central and peripheral nervous systems. UCH-L1 is released into extracellular fluids following neuronal injury, making it a sensitive biomarker for neuronal damage across a wide range of neurological conditions. [@uchlf]
The protein was originally discovered as a neuronal marker (PGP9.5) and later characterized for its enzymatic function. Its neuron-specific expression and release following injury have made it one of the most widely studied neuronal biomarkers. [@uchlg]
| Property | Value |
|---|---|
| Gene | UCHL1 |
| Protein | Ubiquitin C-terminal Hydrolase L1 |
| UniProt | P35571 |
| Molecular Weight | 24.8 kDa (monomer) |
| Chromosome | 4p14 |
| Expression | Neuron-specific (post-mitotic neurons) |
| Function | Deubiquitination, protein quality control |
UCH-L1 is a 223-amino acid protein with:
UCH-L1 is expressed in:
UCH-L1 is one of the most sensitive biomarkers for acute neuronal injury:
In neurodegenerative disease:
| Disease | Elevation | Timing | Utility |
|---|---|---|---|
| TBI | 10-100x | 6-72 hours | Diagnosis, prognosis |
| AD | 1.5-3x | Chronic | Disease monitoring |
| PD | 1.5-2.5x | Chronic | Severity, progression |
| ALS | 2-5x | Chronic | Diagnosis, progression |
| HD | 1.5-3x | Chronic | Disease burden |
Understanding why UCH-L1 is released:
UCH-L1 has been studied in Japanese, Korean, and Chinese populations with population-specific findings:
| Population | TBI Elevation | AD Elevation | PD Elevation | Reference Range |
|---|---|---|---|---|
| Japanese | 10-100x | 1.5-3x | 1.5-2.5x | Similar to Western |
| Korean | 8-80x | 1.5-2.5x | 1.5-2x | Similar to Western |
| Chinese | 10-90x | 1.5-3x | 1.5-2.5x | Similar to Western |
| European | 10-100x | 1.5-3x | 1.5-2.5x | Standard |
| African | 8-80x | 1.3-2.5x | 1.3-2x | May vary |
| Condition | Sensitivity | Specificity | AUC | Cutoff |
|---|---|---|---|---|
| Severe TBI | 85-95% | 90-95% | 0.90-0.96 | >200 pg/mL blood |
| Concussion | 60-75% | 70-80% | 0.68-0.78 | >100 pg/mL blood |
| AD | 65-80% | 70-85% | 0.70-0.82 | >10 ng/mL CSF |
| PD | 60-75% | 65-80% | 0.65-0.78 | >8 ng/mL CSF |
| ALS | 70-85% | 75-90% | 0.75-0.88 | >12 ng/mL CSF |
| HD | 60-75% | 70-85% | 0.68-0.80 | >8 ng/mL CSF |
| Method | Sensitivity | Turnaround | Cost (USD) | FDA Status |
|---|---|---|---|---|
| Banyan BTI (CLIA) | 85-95% | 30 min | $150-200 | FDA cleared (TBI) |
| Simoa | 90-98% | 2-3 days | $200-350 | RUO |
| ELISA | 70-85% | 1-2 days | $50-100 | RUO |
| ECL | 75-90% | 1 day | $75-150 | RUO |
| Western blot | 60-75% | 2-3 days | $75-125 | RUO |
| Region | Status | Details |
|---|---|---|
| United States | FDA Cleared | Banyan BTI cleared for concussion evaluation (2023) |
| Europe | CE-IVD (TBI) | Banyan BTI CE-marked for TBI |
| Japan | PMDA (Research) | No approval; clinical trials ongoing |
| China | NMPA (Research) | No approval; research use |
| Korea | KFDA (Research) | No approval; limited availability |
| Test Type | Cost (USD) | Notes |
|---|---|---|
| FDA-cleared (Banyan) | $150-200 | Point-of-care, concussion |
| Simoa (ultra-sensitive) | $200-350 | Research, low levels |
| ELISA | $50-100 | Standard research |
| CSF analysis | $75-150 | Requires lumbar puncture |
| Combination panel | $250-400 | UCH-L1 + NfL + tau |
Current priorities include:
Multi-analyte panels: Combining UCH-L1 with NfL, tau, and other markers
Longitudinal studies: Establishing as disease progression biomarker
Point-of-care testing: Rapid bedside tests for TBI
Precision medicine: UCH-L1 genotype-guided approaches
Neurofilament Light Chain (NfL) - Biomarker
Neurofilament Heavy Chain (NfH) - Biomarker
Total Tau (t-Tau) - Biomarker
Neuron-Specific Enolase (NSE) - Biomarker
Parkinson's Disease Biomarkers
Alzheimer's Disease Biomarkers
TBI Biomarkers## References